|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500097875 |
|
最近更新日期: Date of Last Refreshed on: |
2025-02-26 16:43:41 |
|
注册时间: Date of Registration: |
2025-02-26 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
糖尿病神经病理性疼痛协同管理试点应用与效果研究 |
|
Public title: |
Research on the application and effect of collaborative management of diabetic neuropathic pain |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
糖尿病神经病理性疼痛协同管理试点应用与效果研究 |
|
Scientific title: |
Research on the application and effect of collaborative management of diabetic neuropathic pain |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
李文硕 |
研究负责人: |
姜莹莹 |
|
Applicant: |
Li Wenshuo |
Study leader: |
Jiang Yingying |
|
申请注册联系人电话: Applicant telephone: |
+86 139 6447 8652 |
研究负责人电话:
Study leader's |
+86 158 1155 8104 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
lws13964478652@163.com |
研究负责人电子邮件: Study leader's E-mail: |
jiangyingying@ncncd.chinacdc.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市西城区南纬路27号 |
研究负责人通讯地址: |
北京市西城区南纬路27号 |
|
Applicant address: |
No.27 Nanwei Road, Xicheng District, Beijing |
Study leader's address: |
No.27 Nanwei Road, Xicheng District, Beijing |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中国疾病预防控制中心慢性非传染性疾病预防控制中心 |
||
|
Applicant's institution: |
National Center for Chronic and Noncommunicable Disease Control and Prevention ,Chinese Center for Disease Control and Prevention |
||
|
研究负责人所在单位: |
中国疾病预防控制中心慢性非传染性疾病预防控制中心 |
||
|
Affiliation of the Leader: |
National Center for Chronic and Noncommunicable Disease Control and Prevention ,Chinese Center for Disease Control and Prevention |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
202452 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国疾控中心慢病中心伦理审查委员会 |
||
|
Name of the ethic committee: |
National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention Ethical Review Committee |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-12-27 00:00:00 | ||
|
伦理委员会联系人: |
赵艳芳 |
||
|
Contact Name of the ethic committee: |
Zhao Yanfang |
||
|
伦理委员会联系地址: |
北京市西城区南纬路27号 |
||
|
Contact Address of the ethic committee: |
No.27 Nanwei Road, Xicheng District, Beijing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 8313 6481 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
中国疾病预防控制中心慢性非传染性疾病预防控制中心 |
||||||||||||||||||||||
|
Primary sponsor: |
National Center for Chronic and Noncommunicable Disease Control and Prevention ,Chinese Centre for Disease Control and Prevention |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市西城区南纬路27号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.27 Nanwei Road, Xicheng District, Beijing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国家重点研发计划课题“基于患者参与的老年神经病理性疼痛协同照护移动平台建设”(2022YFC3602204) |
||||||||||||||||||||||
|
Source(s) of funding: |
Construction of a mobile platform for collaborative care of neuropathic pain in the elderly based on patient participation under the National Key Research and Development Programme of China (2022YFC3602204) |
||||||||||||||||||||||
|
研究疾病: |
糖尿病神经病理性疼痛 |
||||||||||||||||||||||
|
Target disease: |
Diabetic peripheral neuropathic pain |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
整群随机分组 |
||||||||||||||||||||||
|
Study design: |
Cluster randomization |
||||||||||||||||||||||
|
研究目的: |
建立一套“以患者为中心”的DPNP协同管理方案,通过定量研究结果对该方案的有效性进行评价,定性访谈结果分析该方案目前存在的不足及实际实行过程中遇到的问题,对该方案的有效性及可行性进行综合评价,以分析DPNP协同管理方案是否可以被更广泛人群使用。 |
||||||||||||||||||||||
|
Objectives of Study: |
To establish a "patient-centred" DPNP co-management programme, evaluate the effectiveness of the programme through quantitative findings, analyse the shortcomings of the programme and the problems encountered in its actual implementation through qualitative interviews, and carry out a comprehensive evaluation of the programme's effectiveness and feasibility, in order to analyse whether the DPNP co-management programme can be used by a wider range of people. A comprehensive evaluation of the effectiveness and feasibility of the programme was conducted to analyse whether the DPNP could be used by a wider group of people. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
定量研究: 1、群组纳入标准 (1)每个社区可招募20名以上糖尿病患者;(2)各个社区应按区域、所有者、规模、经济水平、医疗条件相匹配;(3)未进行过类似的项目;(4)同意参与项目至少3月;(5)同意安排至少一名全职或兼职项目负责人执行管理干预计划。 2、个体纳入标准 (1)已被二级及以上医院确诊为糖尿病的患者;(2)年龄在35岁及以上;(3)I-DN4量表诊断为糖尿病神经病理性疼痛(得分≥3分);(4)拥有智能手机且可以独立操作智能手机完成发送短信、接打电话、微信聊天等功能;(5)自愿参与为期2个月的DPNP干预管理活动。 定性研究: 1、患者:采用方便抽样抽取干预组患者为研究对象进行访谈。按照信息饱和原则,当访谈者诉说的内容已经达到饱和状态,增加访谈者不会出现其他信息为标准,本次研究样本量约每组10-15人。 2、医护:(1)纳入在中老年DPNP患者治疗或管理领域有一定经验的医生、护士或其他相关专业的医护及管理人员;(2)了解且使用过在线管理平台,能够深入讨论其在实际工作中的应用和影响;(3)了解自我管理小组活动,能够为活动的改善提出专业建议;(4)有较强的表达欲和沟通能力,能够清晰表达对协同管理模式、在线管理平台和自我管理小组活动的看法、效果评估以及应用体会;(5)自愿参与研究,理解并同意定性访谈的目的和程序。 |
||||||||||||||||||||||
|
Inclusion criteria |
Quantitative research: 1 Criteria for Cohort Inclusion (i) More than 20 diabetic patients can be recruited from each community; (ii) Each community should be matched by region, owner, size, economic level, and medical condition; (iii) No similar project has been conducted; (iv) Agree to participate in the project for at least 3 months; (v) Agree to arrange for at least one full-time or part-time project leader to implement the management intervention plan. 2 Individual inclusion criteria (i)Patients who have been diagnosed with diabetes mellitus by secondary or higher hospitals; (ii)Age 35 years and above; (iii)Diagnosed with diabetic neuropathic pain on the I-DN4 scale (score ≥3); (iv) Own smartphones and can independently operate them to complete the functions of sending text messages, answering phone calls, and chatting on WeChat; (v) Voluntarily participate in the DPNP intervention and management programme for a period of 2 months. Qualitative research 1.Patients: convenience sampling was used to select patients in the intervention group to be interviewed for the study. In accordance with the principle of information saturation, when the content of the interviewer has reached saturation, increasing the interviewer will not appear other information as a criterion, the sample size of this study is about 10-15 people per group. 2.Healthcare: (i)Include doctors, nurses or healthcare and management personnel of other related professions who have some experience in the treatment or management of middle-aged and elderly DPNP patients; (ii) Understand and have used the online management platform, and be able to discuss in depth its application and impact in practice; (iii)Understand the activities of the self-management group, and be able to put forward professional suggestions for the improvement of the activities; (iv) Have strong expressive and communication skills, and be able to clearly Strong desire for expression and communication skills, able to clearly express their views on the collaborative management model, online management platform and self-management group activities, as well as their assessment of their effectiveness and experience of their application; (v) Voluntarily participating in the study, understanding and agreeing to the purpose and procedures of the qualitative interviews. |
||||||||||||||||||||||
|
排除标准: |
定量研究: 1、群组排除标准 无。 2、个体排除标准 (1)存在严重智力缺陷或严重精神认知障碍等精神健康问题;(2)语言表达、交流有障碍;(3)未来3个月有计划接受其他干预方法;(4)不同意参加此调查者;(5)正在参与其他研究。 定性研究: 1、患者:不愿参与本研究者。 2、医护:不愿参与本研究者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Quantitative research: 1.Cluster exclusion criteria None. 2.Individual exclusion criteria (1) Mental health problems such as severe intellectual deficits or severe mental cognitive disorders; (2) impaired language expression and communication; (3) plans to receive other intervention methods in the next 3 months; (4) those who do not agree to participate in this survey; (5) those who are participating in other studies. Qualitative research 1.Patients:Those who do not wish to participate in this survey. 2.Heathcare:Those who do not wish to participate in this survey. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-01-01 00:00:00至 To 2025-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-03-07 00:00:00 至 To 2025-03-21 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
采用整群随机抽样方法,由研究人员抽取符合纳入标准的社区,将纳入社区利用随机数表法随机整群分配至对照组和干预组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Whole cluster random sampling method was used, where communities that met the inclusion criteria were selected by the researcher, and the included communities were randomly assigned in whole clusters to the control and intervention groups using the random number table method. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
单盲,不会告知研究对象分组方式和干预内容。 |
|
Blinding: |
Single-blind, study participants will not be informed of the grouping method and the intervention. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
本研究不共享任何研究原始数据,若有相关数据需要,可于2025年12月后向中国疾病预防控中心慢病中心提出数据申请。联系邮箱:lws13964478652@163.com。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
This study does not share any original study data, and if there is a need for relevant data, a data request can be submitted to the Center for Chronic Diseases of the Chinese Center for Disease Control and Prevention after December 2025. Contact email: lws13964478652@163.com. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集:经过培训且合格的调查人员进行基线调查,审核员当场审核数据。 源数据:备份两个及以上u盘或者硬盘中,防止数据出现意外,并且保证数据安全。 采集和录入:双录入的方式,保持数据的准确性。 核对:本次调查会产生电子数据库,国家项目组成员负责数据库的管理,进行每周一次的质控,并反馈质控报告。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection: Trained and qualified investigators conduct the baseline survey and auditors review the data on the spot. Source data: Backup two or more USB flash drives or hard disks to prevent data accidents and ensure data security. Capture and entry: Double-entry method to maintain data accuracy. Verification: The survey will generate an electronic database, and members of the national project team will be responsible for the management of the database, conduct weekly quality control, and provide feedback on the quality control report. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |